Story thread · 2 reports / 1 sources
No Survival Bump in Metastatic NSCLC With Addition of ADC to Immunotherapy
medpagetoday.com · 1d
(MedPage Today) -- Survival in metastatic non-small cell lung cancer (NSCLC) did not improve with the addition of the antibody-drug conjugate (ADC) sacituzumab govitecan (Trodelvy) to immunotherapy, a large randomized trial showed. Median progression...
First report: Local Consolidative Therapy After Dual Immunotherapy Fizzles in Metastatic NSCLC — medpagetoday.com, 2d
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.